IP Library › Granted Patent US 8,734,809
Granted Patent B2
US 8,734,809 · App. 13/322,164 · Granted May 27, 2014

AAV's and uses thereof

Inventors: Guangping Gao (Westborough, MA); Terence Flotte (Holden, MA); Jun Xie (Worcester, MA)
Assignee: University of Massachusetts
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,734,809
App. No.
13/322,164
Granted
May 27, 2014
Kind
B2
Abstract

The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Claims (52)

1. An isolated adeno-associated virus (AAV) capsid protein comprising the amino acid sequence set forth as SEQ ID NO: 103, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 171, 172, 173, 174, 175, 176, 177 or 178.

2. A composition comprising the isolated AAV capsid protein of claim 1 .

3. A composition comprising the isolated AAV capsid protein of claim 1 and a pharmaceutically acceptable carrier.

4. A recombinant AAV (rAAV) comprising the isolated AAV capsid protein of claim 1 .

5. A composition comprising the rAAV of claim 4 .

6. The composition of claim 5 further comprising a pharmaceutically acceptable carrier.

7. A kit comprising:

a container housing a recombinant AAV having an isolated AAV capsid protein of claim 1 .

8. The kit of claim 7 , wherein the container is a syringe.

9. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 103.

10. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 129.

11. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 130.

12. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 131.

13. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 132.

14. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 133.

15. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 134.

16. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 135.

17. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 136.

18. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 137.

19. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 138.

20. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 139.

21. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 140.

22. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 141.

23. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 142.

24. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 143.

25. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 144.

26. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 145.

27. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 146.

28. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 147.

29. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 148.

30. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 149.

31. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 150.

32. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 171.

33. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 172.

34. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 173.

35. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 174.

36. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 175.

37. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 176.

38. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 177.

39. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 178.

40. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 173, and wherein packaged within the rAAV is a nucleic acid comprising a transgene.

41. The rAAV of claim 40 , wherein the transgene comprises a tissue-specific promoter operably linked to a coding sequence.

42. The rAAV of claim 41 , wherein the coding sequence encodes a therapeutic protein.

43. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 174, and wherein packaged within the rAAV is a nucleic acid comprising a transgene.

44. The rAAV of claim 43 , wherein the transgene comprises a tissue-specific promoter operably linked to a coding sequence.

45. The rAAV of claim 44 , wherein the coding sequence encodes a therapeutic protein.

46. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 175, and wherein packaged within the rAAV is a nucleic acid comprising a transgene.

47. The rAAV of claim 46 , wherein the transgene comprises a tissue-specific promoter operably linked to a coding sequence.

48. The rAAV of claim 47 , wherein the coding sequence encodes a therapeutic protein.

49. The rAAV of claim 4 , wherein the AAV capsid protein comprises the amino acid sequence as set forth in SEQ ID NO: 103, and wherein packaged within the rAAV is a nucleic acid comprising a transgene.

50. The rAAV of claim 49 , wherein the transgene comprises a tissue-specific promoter operably linked to a coding sequence.

51. The rAAV of claim 50 , wherein the coding sequence encodes a therapeutic protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2012
From: GAO, GUANGPING; FLOTTE, TERENCE; XIE, JUN
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 029041/0540 →
Continuity (2)
Provisional Application 61182084 · May 28, 2009
Related Publication 20120137379A1 · May 31, 2012